Dynamic Changes of Neuroskeletal Proteins in DRGs Underlie Impaired Axonal Maturation and Progressive Axonal Degeneration in Type 1 Diabetes

Table 1

Clinical data.

		N	Body weight (g)	Blood glucose level (mM)	Insulin pmol/L	C-peptide pmol/L	IGF-1 ng/mL
2-month	Control	8	428 ± 19	5.0 ± 0.4	455 ± 52	710 ± 52	1785 ± 112
	BB/Wor	8	348 ± 21*	24.6 ± 2.2*	57 ± 7*	43 ± 12*	1328 ± 87*
4-month	Control	8	429 ± 22	5.0 ± 0.3	438 ± 27	723 ± 12*	—
	BB/Wor	8	375 ± 15^†	23.9 ± 1.3*	51 ± 6*	<25*	—
7-month	Control	9	505 ± 37	5.3 ± 0.3	526 ± 108	727 ± 24	1182 ± 32
	BB/Wor	9	370 ± 18*	25.2 ± 1.7*	153 ± 55*	<25*	778 ± 70*
10-month	Control	8	555 ± 29	5.0 ± 0.3	506 ± 81	687 ± 18	1192 ± 37
	BB/Wor	8	400 ± 13*	23.2 ± 1.3*	84 ± 21*	<25*	747 ± 86*

Results are means ± SD. ^†𝑃<.01; *𝑃<.001 versus respective control-rats.